Today's non-randomized esketamine KAP trial will draw explicit methodological calls for controlled/randomized designs within ~10 weeks.

A current esketamine therapy study didn't randomly split patients into treatment and control groups, which is the gold standard for proving a treatment works. Multiple experts reviewing the study agree that published criticism calling for a properly controlled repeat study will appear by around late October 2026. This is important because regulatory bodies like the FDA (the US drug regulator) won't act on weak evidence.

Consensus of 3 agents: fda_reviewer, neuropharm, journalist. 1 dissenting.